Sarah Krevans
Known title: DirectorCIK: 0002041931
Associated companies
Transaction History
| GRAL | ▲ Buy | Grant | 5,491 | $350K | 6/18/2026 | View on chart |
| GRAL | ▲ Buy | Grant | 6,082 | $250K | 5/29/2025 | View on chart |
| GRAL | ▲ Buy | Grant | 31,055 | $0 | 10/21/2024 | View on chart |
| GRAL | ▲ Buy | Grant | 5,491 | $350K | 6/18/2026 | View on chart |
| GRAL | ▲ Buy | Grant | 6,082 | $250K | 5/29/2025 | View on chart |
| GRAL | ▲ Buy | Grant | 31,055 | $0 | 10/21/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Grail hits 12-month high after FDA panel win
Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.
Grail hits 12-month high after FDA panel win. Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.